Actineer, a Joint Venture of ITM and CNL, Begins Actinium-225 Production
October 18 2024 - 7:00AM
Business Wire
Successful Cyclotron Irradiation of Ra-226 Sets the Stage for
Actineer's Large-Scale Ac-225 Production for Cancer Therapies
Actineer, the joint venture between ITM and Canadian Nuclear
Laboratories (CNL) Ltd., has successfully produced Actinium-225
(Ac-225) by irradiating Radium-226 (Ra-226) in a cyclotron. This
production milestone achievement will enable the joint venture to
provide GMP-grade Ac-225 to customers by mid-2025, alongside the
submission of a US Drug Master File (DMF).
"Actineer is proud to have reached this important milestone,"
said Ram Mullur, President of Actineer. "This achievement
represents a critical step towards fulfilling our commitment to
becoming a major global supplier of Ac-225. Together, we are
dedicated to serving customers, the medical community, and, most
importantly, patients who rely on Ac-225’s potential to advance
Targeted Alpha Therapy."
Actinium-225 serves as a vital precursor in the development of
innovative cancer therapies. It is especially valuable for use in
drug research and clinical trials focused on Targeted Alpha Therapy
(TAT), where it is combined with molecules designed to seek out and
bind to cancer cells. Once linked, the Ac-225 is delivered to the
tumor, where it has the potential to treat various types of cancers
by attacking cancerous cells while minimizing harm to nearby
healthy tissues. Future drug products using Ac-225, once fully
developed and approved, could offer powerful treatments that
precisely target and destroy cancerous tissue with limited side
effects.
"Actinium-225 represents a transformative opportunity in the
realm of cancer treatment. As we look ahead, the global demand for
Ac-225 is poised to rise sharply, driven by the urgent need for
innovative therapies that can target hard-to-reach tumors and
metastases.” said Dr. Andrew Cavey, CEO, ITM and Actineer Board
Chairman. “Actineer is leading the effort to deliver a stable and
scalable supply of Ac-225 which is essential for advancing clinical
trials and also for making life-saving treatments accessible to
patients worldwide."
Alpha-emitters such as Ac-225 are known for emitting high-energy
alpha particles with a short penetration range, enabling precise
targeting of tumor cells. Preclinical studies of TATs have shown
impressive results, with Ac-225 effectively breaking the DNA bonds
of cancer cells, leading to their destruction.
Actineer is focused on expanding manufacturing capacity and
increasing the supply of Ac-225, ensuring that patients worldwide
will benefit from this promising isotope as a foundation for future
cancer therapies.
About Actineer, Inc.
Actineer™ Inc. is a joint venture company between Canadian
Nuclear Laboratories (CNL) and ITM Isotope Technologies Munich SE
(ITM) dedicated to advancing Ac-225 technologies, quickly securing
supply, and producing industrial-scale quantities of this valuable,
rare medical radioisotope for the treatment of cancer. Founded in
October 2023, Actineer™ Inc. together with its strong supply chain
collaborators will progress Ac-225 development, production and
processing technologies. It has established short-term production
capabilities that is expected to lead to significantly boosting
international supplies, while working long-term towards the
construction of a new Actinium Production Facility (APF) in Canada.
The joint venture’s mission is to fulfil the unmet global
manufacturing and production needs of this coveted radioisotope
with significant potential in the fight against cancer.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241018503210/en/
Actineer, Inc Science Collaboration Centre 286 Plant Road Chalk
River, Ontario, KOJ 1J0 Canada info@actineer.com
For media inquiries only: actineer@trophic.eu